19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace.

SCAMHC serves all individuals regardless of inability to pay. Discounts for essential services are offered based on family size and income. For more information, contact (334) 222-2523 or our 24/7 Helpline at 1-877-530-0002.



powered by centersite dot net
Alzheimers Disease and other Cognitive Disorders
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest NewsQuestions and AnswersVideosLinksBook Reviews
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Research and Prognosis on Alzheimer's Disease

Rudolph C. Hatfield, PhD., edited by Kathryn Patricelli, MA

Treatment Research

study materials At the time of this writing there are well over 100 different medications being investigated in research trials for treating Alzheimer's disease. These medications are at different stages in the research process and:

  • The majority of these drugs are what are called modifying therapies. These are hoped to be able to change or alter how the disease progresses.
  • A smaller number are cognitive enhancers. These are designed to improve cognitive functions like memory or attention.
  • An even smaller number are symptomatic agents. This means that they just work on specific symptoms like agitation, hallucinations (seeing or hearing things that are not there), etc.

The process of approving drugs is often lengthy and consists of many steps. Initial steps are designed to test the safety of the drug. Then the next steps test to see if the drug works or does what it is supposed to do. The final two steps continue with evaluating its safety and effectiveness, as well as how it works when released on the market. Even though there are hundreds of drugs currently in development for Alzheimer's disease, it is a good bet that very few of them will get approval.

Other research that may assist in the development of treatment for Alzheimer's disease includes genetic research. This research is consistently uncovering new genetic associations that may lead to the development of Alzheimer's disease in some people. However, the path from understanding how a particular gene contributes to the development of the issues in Alzheimer's disease and in developing a medication to address that issue can take many years.


At the current time, there are only a few medications that are approved for the treatment of Alzheimer's disease. It is important to understand that these medications do not reverse or cure the disease. People who have Alzheimer's disease may live between one to twenty years after they are diagnosed with the disorder. The average length of time people live after the diagnosis is made is about eight years. However, there can be quite a bit of variation from person-to-person. Most often people with Alzheimer's disease die from other medical conditions that are complications of the disorder including pneumonia or from other factors such as heart disease.